Second Evotec BMS Molecular Glue Candidate Reaches IND

Evotec reported November 19 that the FDA accepted an IND for a second candidate from its Bristol Myers Squibb molecular-glue collaboration. It is a development-enabling regulatory step, not clinical data or approval.









